PanCryos is dedicated to developing a safe, scalable, and cost-efficient cell replacement therapy to improve quality of life of millions of people suffering from insulin-dependent diabetes. PanCryos has established a simplified and effective method to generate stem cell derived glucose responsive beta cells. This promising cell therapy, PanINSULA™, is in preclinical development and protected by IP licensed from Copenhagen University. PanCryos has started a capital raise to support the journey towards a phase I/IIa clinical trial in 2022 and the team is open to discuss partnerships that can promote a cell therapy solution in diabetes.

Contact name:

Jacqueline Ameri


Ole Maaløes Vej 3, c/o BioInnovation Institute, 2200 Copenhagen N, Denmark


+ 46 704 151 746

Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2019 DANISH BIO – DANSK BIOTEK. All rights reserved.